ࡱ> q` RYbjbjqPqP::T#)) ///8L/L/.F8080(`0`0`0111qssssss$thܣ6Q81"188 `0`0eu<u<u<8r .`0`0qu<8qu<u<b1$`0,0 0Y/_:UV͜0.A;,13u<3u4x111<^111.8888d -$ -   Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.q\qge兡N gPlQSShandong Xinhua Pharmaceutical Company Limited(a joint stock company established in the People s Republic of China with limited liability)(Stock Code: 0719)CONTINUING CONNECTED TRANSACTIONContinuing connected transaction between the Company and SXPGCThe Board announces that on 23 March 2012, the Company and SXPGC entered into the Supplemental Trademark Licence Agreement which amends and supplements the Trademark Licence Agreement. Pursuant to the Supplemental Trademark Licence Agreement, the annual licence fee for the Company to use the Trademark is RMB10,000,000 for the period between 1 April 2012 to 31 December 2014 and the Company has to pay to the annual licence fee to SXPGC on or before 30 June of each year. Other terms of the Trademark Licence Agreement remain unchanged. The Supplemental Trademark Licence Agreement commenced on 1 April 2012 and will expire on 31 December 2014.As at the date of this announcement, SXPGC holds 36.32% equity interest of the Company and is a substantial shareholder of the Company. Therefore, SXPGC is a connected person under the Listing Rules. The transactions contemplated under the Supplemental Trademark Licence Agreement will constitute a continuing connected transaction under the Listing Rules. Implications under the Listing RulesThe annual cap for the Supplemental Trademark Licence Agreement is RMB 10,000,000. The applicable percentage ratios (as defined in the Listing Rules) are less than 5% on an annual basis. In accordance with rule 14A.34 of the Listing Rules, the continuing connected transaction contemplated under the Supplemental Trademark Licence Agreement is only subject to the reporting and announcement requirements under rules 14A.45 to 14A.47 of the Listing Rules, the annual review requirements under rules 14A.37 to 14A.40 of the Listing Rules and the requirements set out in 14A.35(1) and 14A.35(2) of the Listing Rules. The continuing connected transaction contemplated under the Supplemental Trademark Licence Agreement is exempt from the Independent Shareholders approval requirements.Background InformationReference is made to the announcement dated 28 October 2009. On 7 December 1996, the Company and SXPGC entered into the Trademark Licence Agreement pursuant to which the Company was granted by SXPGC the exclusive right to use the Trademark for its existing and future products in and outside the PRC for an indefinite period as long as the PRC registration of the Trademark continues to be valid and the Company continues to use the Trademark. The cap for the annual licence fee under the Trademark Licence Agreement was RMB1,100,000. The cap and the terms of the Trademark Licence Agreement were approved by the Independent Shareholders at the extraordinary general meeting held on 29 December 2006. Supplemental Trademark Licence AgreementPrincipal terms of the Supplemental Trademark Licence AgreementDate : 23 March 2012Parties : (i) the Company (ii) SXPGCOn 23 March 2012, the Company and SXPGC entered into the Supplemental Trademark Licence Agreement which amends and supplements the Trademark Licence Agreement. Pursuant to the Supplemental Trademark Licence Agreement, the annual licence fee for the Company to use the Trademark is RMB10,000,000 for the period between 1 April 2012 to 31 December 2014 and the Company has to pay to the annual licence fee to SXPGC on or before 30 June of each year. Other terms of the Trademark Licence Agreement remain unchanged. The Supplemental Trademark Licence Agreement commenced on 1 April 2012 and will expire on 31 December 2014.Basis upon which the new cap is determinedIn determining the new cap, the Company has taken into consideration of the following factors:the increase in the branding effect of the Trademark; and (b) the increase in the sales scale of the products that use the Trademark. Reasons for and benefits of the continuing connected transaction between the Company and SXPGCBy virtue of the Trademark Licence Agreement and the Supplemental Trademark Licence Agreement, the Company will be able to continue to use the Trademark on marketing and the current and future production of its products in and outside the PRC which is essential for the continued running of the Company. The Directors (including the independent non-executive directors of the Company) consider that:the entering into the Supplemental Trademark Licence Agreement is in the interest of the Company and its Shareholders as a whole; the continuing connected transaction contemplated under the Supplemental Trademark Licence Agreement is on normal commercial terms and in the ordinary and usual course of business; and the terms of the continuing connected transaction contemplated under the Supplemental Trademark Licence Agreement are fair and reasonable.None of the Directors has a material interest in the continuing connected transaction and therefore no Director is required to abstain from voting on the board resolution in relation to the continuing connected transaction.Connected RelationshipAs at the date of this announcement, SXPGC holds 36.32% equity interest of the Company and is a substantial shareholder of the Company. Therefore, SXPGC is a connected person under the Listing Rules. The transactions contemplated under the Supplemental Trademark Licence Agreement will constitute a continuing connected transaction under the Listing Rules. Implications under the Listing RulesThe annual cap for the Supplemental Trademark Licence Agreement is RMB 10,000,000. The applicable percentage ratios (as defined in the Listing Rules) are less than 5% on an annual basis. In accordance with rule 14A.34 of the Listing Rules, the continuing connected transaction contemplated under the Supplemental Trademark Licence Agreement is only subject to the reporting and announcement requirements under rules 14A.45 to 14A.47 of the Listing Rules, the annual review requirements under rules 14A.37 to 14A.40 of the Listing Rules and the requirements set out in 14A.35(1) and 14A.35(2) of the Listing Rules. The continuing connected transaction contemplated under the Supplemental Trademark Licence Agreement is exempt from the Independent Shareholders approval requirements. Information about the Company and SXPGCThe Company is mainly engaged in the development, manufacture and sales of bulk pharmaceuticals, preparations and chemicals products.SXPGC is a state-owned enterprise established in the PRC specialising in investment in the pharmaceutical industry, and associated chemical production, packaging and supply of chemical engineering equipment. DefinitionsIn this announcement, the following expressions have the meanings set out below unless the context requires otherwise:Boardmeans the board of Directors of the Company;Company means q\qge兡N gPlQS (Shandong Xinhua Pharmaceutical Company Limited), a joint stock company incorporated in the PRC with limited liability; Directors means the directors of the Company including the independent non-executive directors of the Company;Independent Shareholdersmeans the Shareholders other than SXPGC and its respective associates (as defined in the Listing Rules);Listing Rulesmeans the Rules Governing the Listing of Securities on the Stock Exchange;PRC means the Peoples Republic of China;RMB means Renminbi, the lawful currency of the PRC for the time being;Trademarkmeans the trademark Xinhua;Trademark Licence Agreementmeans the supplemental trademark licence agreement entered into between the Company and SXPGC dated 7 December 1996;Shareholdersmeans the shareholders of the Company; Stock Exchange means The Stock Exchange of Hong Kong Limited;Supplemental Trademark Licence Agreementmeans the supplemental trademark licence agreement entered into between the Company and SXPGC dated 23 March 2012; andSXPGC means 6c d y z { | ~  x 4 Z \   , 4 6 8 9 мrd]YNhFPJnHo(tHhF hsZhFhsZhsZPJnHo(tHhFKHPJnHo(tHhF5KHPJ\nHo(tHhFCJPJo( hF6]hFCJo(hFnHo(tHhF6]o( hFo('jhF6U]mHnHo(tHuhFKHaJhF6KH]aJo(hF6KH]aJhF6KH]aJnHo(tH z | } ~   x 2 4 Z \   +,$If $$G$H$Ifa$$G$IfVD^$G$H$a$G$H$$G$H$a$G$H$ $7$8$G$H$a$6YYY9 J P b PinrsYfs%'59>]mxƹxoooohFnHo(tHhF5\o(hF5KH\aJo(hFKHaJhFKHPJaJnHo(tHhFKHaJo(hFKHaJnHo(tHhFKHPJnHo(tHhFPJnHo(tH hFo(hFhFKHPJnHo(tH hFKHhFKHo(hFKHnHo(tH*&'89:QR{l$7$8$G$H$^a$$7$8$G$H$`a$ $7$8$G$H$a$[kd$$Ifq!!064 qa$$7$8$G$H$Ifa$  78:QLTAjp   s   -µžͨͨͨӨӨhsZPJnHo(tHhF5KH\o(hFKHPJnHo(tHhsZKHPJnHo(tHhFKHnHo(tH hFKHhFKHo(hF5\o(hF hFo(hFnHo(tHhFPJnHo(tH:@A$7$8$G$H$^a$$77$8$G$H$^7a$$77$8$G$H$^7a$$77$8$G$H$^7a$ $7$8$G$H$a$$7$8$G$H$`a$$7$8$G$H$VD^a$01\]FG$:7$8$G$H$VDWD^`:a$$7$8$G$H$a$$ & F'7$8$G$H$a$VD$7$8$G$H$VD^a$ $7$8$G$H$a$ $7G$H$^7a$$7$8$G$H$^a$-.1\EFGOShr789Kx%pqrvx|򼰼뉀qhFKHPJaJnHo(tHhFKHaJo(hFKHaJnHo(tHhFKHaJo(hFKHaJhFKHaJo(hF5KH\aJo(hF5KH\aJnHo(tHhFB*KHo(ph hFKHhFPJaJnHo(tHhFKHo(hFKHPJnHo(tH&G89wxe f # $7$8$G$H$a$$77$8$G$H$^7a$$ & F(7$8$G$H$a$$7$8$G$H$VD^a$$77$8$G$H$^7a$9N"23itK P e f "!+!/!E!######M$$$!%ķ̆}}}v}k}gkhFhFPJnHo(tHhFKHo(hFnHo(tH hFo(hF5KH\aJo(hFKHaJhFKHPJaJnHo(tHhFKHaJo(hFKHaJnHo(tHhFnHtHhF5\o(hFPJnHtHhFB*PJaJnHphtH"hFB*PJaJnHo(phtH'####N$O$!%"%/%0%%%%%%$$7$8$G$H$Ifa$ $7$8$G$H$If7$8$G$H$ 7G$^7G$$7d^7`$77$8$H$^7a$$77$8$G$H$^7a$!%"%#%$%/%0%%%%%%%%%%$&F&H&&&''0'<'v'((((("(&((((((((((())))Z)^)_)h))))))ѾhFKHaJhFKHaJo(hFKHo( hFKHhF5KH\aJo(%hFCJOJPJQJaJnHo(tHhFCJOJPJQJaJ%hFCJOJPJQJaJnHo(tHhFCJOJPJQJaJ6%%%'''2'''LLkd$$If0 ! 64 a8$$7$8$G$H$Ifa$ $7$8$G$H$IfLkd$$If0 ! 64 a8'((((((((LLkd$$If0 ! 64 a8$$7$8$G$H$Ifa$ $7$8$G$H$IfLkdh$$If0 ! 64 a8((())))\)])LLkd$$If0 ! 64 a8$$7$8$G$H$Ifa$ $7$8$G$H$IfLkdH$$If0 ! 64 a8])^)j)k)))))*LLkd$$If0 ! 64 a8$$7$8$G$H$Ifa$ $7$8$G$H$IfLkd($$If0 ! 64 a8))** *!*-*.*0*X*Y*j*p*****,+4+8+9+?+@+A+F+G+,TTTTTTUUUUUV¶ޅvnhFKHaJhFKHPJaJnHo(tHhFKHaJnHo(tH hFaJhFPJaJnHo(tHhFaJo(hFB*aJphhFB*aJo(phUhFKHPJnHo(tHhsZKHPJnHo(tHhFKHo(hFKHnHo(tH hFKHhFKHnHtH&** */*0*X*Y*k**LLkdx$$If0 ! 64 a8 $7$8$G$H$IfLkd$$If0 ! 64 a8$$7$8$G$H$Ifa$*****?+@+I+J+LLkdX$$If0 ! 64 a8 $7$8$G$H$IfLkd$$If0 ! 64 a8$$7$8$G$H$Ifa$q\qgeƖW gPNlQS(Shandong Xinhua Pharmaceutical Group Company Limited), a wholly-state owned company which holds and owns 36.32% of the total issued share capital of the Company and is currently the largest shareholder of the Company.By Order of the BoardShandong Xinhua Pharmaceutical Company LimitedZhang DaimingChairman23 March 2012, Zibo, PRCAs at the date of this announcement, the Board comprises: Executive Directors:Mr. Zhang Daiming (Chairman)Mr. Du DepingMr. Zhao SongguoIndependent Non-executive Directors:Mr. Zhu BaoquanMr. Bai HuiliangMr. Kwong Chi Kit, VictorNon-executive Directors: Mr. Ren FulongMr. Xu LieMr. Zhao BinPAGE 1PAGE 5J+UUUUUUVfVVwwd$< 7$8$G$H$^ a$$ 7$8$G$H$^ a$ $7$8$G$H$a$$7$8$G$H$^`a$Lkd$$If0 ! 64 a8$$7$8$G$H$Ifa$ VTVVVfVVVVVVVVVVVVpWrWvWWWWWWWWZXtXXXXXYY.Y4Y6Y8YY¹zzzzzzozozozzgcghCjhCUhFPJnHo(tHhFnHtHhFnHo(tH hFo(hFKHaJhFKHPJnHo(tHhFKHo(hK]KHPJnHo(tHhFKHaJo(hF6KH]aJhF6KH]aJo(hF5KH\aJnHo(tHhF5KH\aJo(hF5KH\aJ&VVVVVVBWDWnWWWWW2XRXtXXX $$G$Ifa$$G$a$ $7$8$G$H$a$$, 7$8$G$H$^ a$XXXXY.Y0Y2Y4Y6Y:YYBYDYHYJYNYPYRYTY`YbYdYfYhYlYnYzY|Y~YYYYYYYYػ hFo(hFCJo(h0JmHnHuhF0JmHnHu hF0JjhF0JUhFhF6]o(jhCUhCYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYY/0P/ =!"#$n% nu*l?xK-PNG  IHDRryJzgAMA pHYsLLXtcPLTE#$ 84*&'"51;7.*?;2-2./+40)%(#,(=9950,+'=83.627383B>B?A=C?@=QNUQNJFBJFXU\Y^[DAZWIF]ZOKHDWSQMMJKHSOD@YUVSLISPFCYV[W^ZROLHOLWTb_`\a^b^`]iftrfc}pn|ymjxupmvtywc`li~{}{wt}{rogdvsda~{xuebnkkgkholtqheqnpnspzw{x~}ƵG'IDATx}|yNg˲$Dz6d[r^ 8&!iP*`Ԙ˒lbh^ZQ@!M#'MI4mt/kvӦMO$nwvgyfgwgt7<3(Z8˱!}t%O_dKU}*meDW܇lL7{]+>IcMC|l4IzO̚*Irìi.! gKz8T*%,佫X ˏ<&K$]vUtɑ,VEzIyH.#Ϛ!tifPIѳf$]Nfx$]F䜳fX$]>.fpHl]Κatg&o#K>k.8ietgƾUFI9|֌4&(D2I$ʴ[K\Co~$]YgȎ*FC$A#eY/c#"OFj+ <#۠1kZǮWM?f5$=Y!R+K.>k*qبPެM`$oY _&I1k̊/ 6/~"G̚J]Y͠E-%B$cJME.s`SϒrĬ9ö"^}2JOfdGʶ*Fwt%YSYw-V21 1y oU2l"lJK=G5ڠ}>i&{1kF%03%)Iy?|Tjzώ|vK{Áw돳L&)sI:i<";ZKܔ{< 5$1FT=twLW|^2? 6{) _%R;I1fI~3Dv F)+I3kFf4b[jNv)I3k* 5lc557{"bcfMsWz_&[lJ@E"̚ K,iM%]r̬IUlr̙p +颐cfM ߽٨Ɇ7t1QQai˿.9fdUll)] @5mB*ëN* tQ~͗26w_pS Iw5km{ޕCL3u B]!G͚,6gt9fִ: qsѪ”%(Y(iD TW#fMA$)/pY AA8z=CfMQ`J/{]MYS:Naq&(D08J;0tCfMQ@ "4\ҝfȶsidz?t;"G͚DtGaJJrܬs"paL IE5yBRlLB ͚.BSl鱊1;K;O9kz~"bsz s[QG#gMe~6iDjcLI!GΚ~ؤS\m%]Κ~$N#)}BܬQ`]j]|sa\Q#y0Y >/ <ʔ>&FzQœt/8EXlFt<ʔ_k=+= 071ox ɕpAqQj] *>~.6Q,tzM (Q_6\#frRLQB]uIRvpzM eۣ|mwJ63;VVX RԣLQ']iѧ3O޵ˍznq(ybE>)ΉFIX88S:U ,U3sdθT`"NBBonaEBORVV+x2j ' s%NR08E=ƓGVhbf#i+zbiӪ8SR"DKnb5rSWMu;6rH[!V#3S0Ow.Bd.A#[̕`XPg #ȂE#/93fZeɌ\S{<03Ol#4 2)J{d<=`[Sԗ ˀ\S%-x,-|@u=݅}55FJ77(\dcs'`}IIFKgnFmNڳw8B?Hz,s-ډ-}ֽ-V,a \954O|\*Kѹ\nW"ZO_^6MSa&y <07t|-s<7{<2*C6m,^YZ=@9Q(iE0b+ANlzQ~O9Q_\jVv^X !*y{F0DiR#ϲӓO5||@c|ȋA^Ɍ=t*"GIgPݙ-M> 9RP86uimڰJsp>/;|(|=i :\2noi@ Wߍ}kj qg@>a19i?K]~되>>7xlgߗ@g sh.~K|~ xs>"¹7U­Ůһ4vvg^i4so8xgkSdpG+'rmS}̈́ð)wh39jkku?ʒa@VfN6:%BwSTjc9u h5#p%k _=ANWvm)eͯlW+RuKw)]zYv})K-_%)kxb[nZ TVdxN~Uwjb;? bPVWȵ!|,<}qP ~9kZgL/g}lIV6z tNyPw\ܵ!1[gtwA[h%#N0y@d z|+C ŕ5G.Yn1<'`MMM7}dy(B#,yKg\7S;w²n r<0w :ҹ0)oux9֖~e⯖gs4[_Sۿ[ rf;G^8}EO{뢂G\Y/XId(Wp=Lh+ve7(so+}Gi'Mp_kk'KD74mфG-1 >cUƱe9 +5?r/:i@~D Gu݅fIZ`UEN 'D%=u\ 3A~ YoaEٷs7Dޠ_E8@-J1|s )rOAO.мE%!185<Ӧi_r`/qc/*!wR?̱+[=aǎ0{̱~}ee];Mf-nz1_W<o5O_cc>YF3>xפ@r.GΏcM]G}EuT)My+78ϻﵱ7Wa=U=_sYjr uK7xCuQ_?Yf n% ؜G-Y`n9 R9؆۳˔F„܀?mG^ {:Fߘ2C7CTk=\@pFk}j&'jv r5qC[:+@ުv߈MarCij BNԓ~P-w9j| 4E"G9 eljUc9!~sS̊PSFF:"YeSC\yHf GL2;6h3c&TiWyf|;tk$o59Yh{w{QȉJN,tΐH#\2*ّ$ʥ ~G0M}"'߇ǽ#FCx#;]vkr"']yVjMN\wn^ZǡWZ#Oo3w,J1G%EBOM_!X#ׯͦۡ"'rLQ5r})mx }M(%r3>QH}/yfN^܌ur"ȹOf5Z.\F|ߩch !~ kn*e#7vReUS8%!G~e`[pCheeAUsn+dz.~#GF3ܟ 9fu<' tW:H<:Kg I;N]:֜op?vԼ,Bkm܍VE8'w c$a_SPTVn58pi.7Ȋ|֜N)meX>wK*)07f^xz)G4w0oVjtP\RQ^so= PկMAwoIң_:û]ul#t0tHq}g:v.;'ѻ\^Vz9WʽRm5ݪ~yv N}Y!Pr&lj&(9f4@k|9!KE\oEqo*<#Z8kcu#QMe"w,:p/ė%"'W+S3'rN"Cr{\]^-P:~pOqL /r[+:@0#ֳ!9bb0,~[;|oB-l$rS't| !G4>ޱ ANg\RSVtDåZ-rTuif=˿1ȭ$K!O8f;`ŽsݦFvzozpWލ+++^=aG>@W2۱ή^=":۷{Eeu}sǂX>h#'Jg 3'U y>K ;rMyUQ v77- ?r*3arCޛ}u7^=n^n7]Vjz~T,PT|' %zo^ IL]" *^e6rg2OCy|l oPVmR rK?1f>B7pvk^77eT$r*gFE/AFj69iF= )N75u cy~iFƧ s|n14#kꑎ,EwA"^(m<x$|Drn=2P Wʻ Sp J<񉲋Jܔ3U=F/5>JtM"@4j|:@ !,rE/*քU5lώU}Mmy=wMu%{nA܇+ߒnzkݼhMBt#`+iyWw T?%EeM}'jӖb76f5`D<$Z $}7uQdk"%Z CrŃ⏤79#㦪5ǥDxOQEWaTnePu}?L(*hc^*R^QbEP/{ |%.#;f?d ?iKz $"l+is=x(J|kc.85`(hJ(l_sY^c%NQHiЕĶXĻCY#+=raDF+CBb~X?ĉx >< ptAwEԜӇjZRI7f. qmZ8CbeA!x%%p/ =K5Q$ݴkG\#^UC6I7rfU;o6n^6 _)ꊝeml 1vi,w.x4̉J.8IoIýlw'kmb JSQ>c釐<7 HһGGZSKG{WD{s{i\^6 <$=ߍq3htcS<W} 4|lMbϛvU*=8N1g,3{6]"Iqԋ[$|V'[g 4rgrH:X^6rWoqH8*n+t0E}hW f%&PQ U籤CE<L%.Iq`JmDCB*KHPJaJnHtH$A@$ ؞k=W[SOFi@F nfh*KHOJPJQJnHtHhS@h ckee,g)ۏ 3$$7$8$G$H$^a$KHPJWDFnHtH.. yblFhe,gCJaJpOpChar Char Char Chard1$CJKHPJaJmHnHtHu\O\ Default1$7$8$H$%B*CJ_HaJmH nHphsH tH6O6 Default1 B*ph,O, cke1 B*ph  !"#$%&'(#$   !&%$#""  &    !%# ''(  !"#$%&'(+     !"#$%&'#j #K0 K0 z|}~,-NO   12?@AC;<wx%&;<cd{|  FG&'/0]^ighiJKLSyz{   0 1 !!!!!!!!!"""""Z"["p""""""""###)#8#C#P#Q#R#S#T#V#W#Y#Z#\#]#_#`#a#b#m#n#o#z#{#|#}#~#########################################0000000000000000000000000 0 0000000000000000h' 00000( 00( 00( 0000000000800H0H0HH0HH0H00000 0 0 0 00 0 0 00 0 00 0 0 0 00 0 0 00 0 0 00 0 00 0 0 00 00 0 00 0 0 0 00 0 00 0 0 00 00 0 000000000000000000 00000 0 00000 0 0 0@0I00@0I00@0I00@0I00@0@0@0@0@0@0@0@0I00000000000000000000000000000000000000000-NO #K0I0I0I0K0K0 K0 (((+9 -!%)V>YY "'.2G#%'(])**J+VXk/0h{c  uo+ :%M bU^X.` KP $Y[T^T3j s/?!c0 $%̛P& Q.'FFk4C41e$M8NyeW:Xi9AT~ZALldDNtT&_[Fd\I\FGKLjE|Lb7Q 'C U8CYR-J^sB`6sRdzke$M8 TiT3j Y[{c 7Q:%M E|Lmw-J^//?!ukxQ.'sRdi9A\IwoB`yeW:P& $%dDZAKP vW~GK&_[Fo+ Zs8f((%        Zn       r        Z)        f#h        ’                         x0>b*       oTԚ=      Gi                          f:Ob|       &"N                 :        g0       H{*       UPe       b        D        ,:        J         Lr        f6                          X"        tX        H        J                  Jmwld      6N        }`        *        ܞ        4         e        CsZK]FO '0]^ihiKLSz{  1 !!"[""##Q#R#S##@  $Y Lii #@@@ @@@&@P@@TUnknownGz Times New Roman5Symbol3& z ArialC .PMingLiUe0}fԚ;[SOSimSun] Times-BoldTimes New RomanQ MSung-LightPMingLiU_ Times-RomanTimes New Roman 1he)E@E@!?!),.:;?]}    " % & ' 2 t%00 0 000000013468:<>@BDOPQRTUVWZ\^ \]d([{  5 0 0 00000579;=?ACY[][dB#B# 2qHX?sZ2~The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representationAChanhggSf(                           ! " # $ % & ' Oh+'0(4DP\l |   The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representationAChanNormal6Microsoft Office Word@@C @FG@vDE՜.+,0 X`t|  Charltons@B#   !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJLMNOPQRTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~Root Entry F gData K1TableSWordDocumentSummaryInformation(DocumentSummaryInformation8CompObjm  FMicrosoft Office Word ĵ MSWordDocWord.Document.89q